Original source text
Key Takeaways BrightSpring's Q2 revenues rose 23%, while adjusted EBITDA climbed 44% and margins expanded 80 basis points.OPCH's Q2 sales rose 2%, as acute therapies grew at a high-single-digit rate and chronic revenues stabilized.BrightSpring expects 17-19.5% revenue growth in 2026, supported by specialty, infusion and provider services. BrightSpring Health Services (BTSG - Free Report) and Option Care Health (OPCH - Free Report) are positioned to benefit from the continued migration of complex care into lower-cost home and alternate settings. BTSG has gained 34.2% over the past six months, while OPCH shares declined 15.8%. In the same period, the Zacks Medical sector registered a 11.2% gain while the S&P 500 Index advanced 21.1%.
BTSG combines pharmacy and provider services, while OPCH has a more concentrated home-infusion model. Both companies see opportunities in specialty therapies and home-based care through the remainder of 2026, but their growth drivers differ.
BrightSpring Health Servicesoperates across Specialty and Infusion Pharmacy, Home and Community Pharmacy, home health, hospice, rehab and personal care. OPCH is more concentrated in home and alternate-site infusion, supported by specialty pharmacies, nursing capabilities and more than 190 facilities. Thus, they overlap in specialty pharmacy and infusion, while BTSG has materially broader exposure to provider services and other home-based categories.
6-Month Price Performance
Image Source: Zacks Investment Research
BTSG Delivers Higher Revenue GrowthBTSG generated $3.9 billion in second-quarter revenues, up 23% year over year, with Pharmacy Solutions increasing 22% and Provider Services up 30%. Specialty and Infusion revenues rose 30%, with scripts up 31%. Management raised 2026 revenue guidance to $15.1-$15.425 billion.
OPCH reported second-quarter revenues of $1.4 billion, up 2% year over year and 7% sequentially. Acute therapies delivered high-single-digit organic growth, while chronic revenues stabilized sequentially. Full-year revenue guidance remains at $5.675-$5.775 billion, pointing to a more measured growth trajectory.
BTSG Records Stronger EBITDA Growth Than OPCHBTSG's second-quarter adjusted EBITDA increased 44% to $206 million, with a 5.3% margin, up 80 basis points. Provider Services EBITDA margin reached 16.1%, while scale, procurement, lean initiatives and technology supported operating leverage.
OPCH's adjusted EBITDA increased 3% to $117.5 million and 12% sequentially. SG&A declined 3% year over year, helping offset modest revenue growth. Full-year adjusted EBITDA is projected to be in the band of $480-$495 million.
BTSG and OPCH Hold Growth PotentialBTSG's Pharmacy Solutions remains its central growth engine. Specialty is expanding beyond branded oncology limited-distribution drugs into rare, orphan and other complex therapies, while Infusion is adding acute and chronic markets. The company continues growing Home and Community Pharmacy across assisted living, hospice, PACE and skilled nursing.
BTSG is combining organic growth with disciplined M&A. Amedisys and LHC integration is progressing well and isexpected to account for roughly $35 million of EBITDA in 2026. Management has completed several smaller tuck-ins and geographic expansions and sees additional opportunities in the second half.
OPCH continues to build around acute, chronic, rare and orphan therapies. Its ambulatory infusion network reached 28 locations, with visits increasing 14% year over year. The company is also seeing opportunities as more oncology therapies move toward infusion clinics and home setting.
OPCH emphasizes organic investment, capacity expansion and cost optimization, while continuing to evaluate adjacency and tuck-in acquisitions. Its capital allocation remains focused on organic investment, buybacks and selective M&A.
BTSG's growth is likely to be driven by specialty-drug launches, infusion expansion, home-health volume growth, value-based care, payer partnerships and technology-enabled productivity. Management is deploying AI and automation across hiring, documentation, medication reviews and patient-care plans. OPCH is likely to benefit from continued site-of-care migration, new infused and injectable therapies, oncology expansion and greater utilization of ambulatory infusion clinics. Its payer and pharma relationships also support commercialization and cost-saving initiatives.
3-Year EPS F12M of BTSG vs OPCH
Image Source: Zacks Investment Research
Key Risks for BTSG and OPCHBTSG must continue managing reimbursement and policy changes, integration execution and labor-related operating costs as it scales. OPCH faces a more immediate chronic-therapy challenge — management expects roughly 600 basis points of revenue headwinds and a $55 million gross-profit headwind in 2026. Payer and formulary changes and therapy-mix volatility remain additional risks.
Valuation: BTSG vs OPCHBTSG's P/E F12M of 26.3 is above the 21 Zacks Medical sector multiple as well as its three-year median of 22.18. The premium reflects stronger growth expectations, but leaves comparatively less valuation cushion if execution or reimbursement trends weaken.
OPCH currently trades at 11.33 P/E F12M earnings, below the 20.93 Zacks Medical sector multiple and its three-year median of 20.19. The discount offers valuation support, although it also reflects the company's slower growth profile and ongoing chronic-therapy pressures.
3-Year P/E F12M for BTSG vs OPCH
Image Source: Zacks Investment Research
Sales and EPS EstimatesBTSG's 2026 estimates call for sales of $15.3 billion, up 18.5%, and EPS of $1.82, up 82%. EPS estimates have improved 8.3% over the past 60 days. OPCH estimates call for sales of $5.76 billion, up 1.9%, and EPS of $1.87, up 8.7%. EPS estimates have improved 2.2% over the past 60 days. The key distinction is that BTSG combines faster projected revenue and EPS growth with stronger estimate revisions, while OPCH’s lower valuation is accompanied by a more modest earnings trajectory.
ConclusionBoth BTSG and OPCH participate in the long-term shift toward home and alternate-site care, specialty therapies and payer-driven cost optimization. BTSG combines specialty pharmacy, infusion and provider services, giving it multiple avenues for growth. OPCH, by contrast, offers a focused infusion platform, improving acute-care momentum and expanding clinics, while its chronic reset remains an important overhang.
BTSG’s 2026 guidance calls for 17-19.5% revenue growth and 32.8-36.8% adjusted EBITDA growth, while consensus EPS estimates point to 82% growth. The higher valuation requires sustained execution. However, BTSG’s Zacks Rank #1 (Strong Buy) compared with OPCH’s Zacks Rank #2 (Buy), along with stronger expected growth and improving operating leverage, highlights the key differences between the two stocks. You can see the complete list of today’s Zacks #1 Rank stocks here.
